Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Acute cerebrovascular events once dominated efforts to protect the brain from cardiovascular disease.
Why it matters
This review describes how vascular injury and Alzheimer pathology commonly coexist and how accumulated vascular damage may lower the threshold at which Alzheimer pathology becomes clinically expressed. It discusses blood pressure evidence from several trials but reports no treatment that cures or prevents Alzheimer's disease.
-
Europe's ageing population is transforming universal healthcare from a financing challenge into a delivery-capacity challenge.
Why it matters
This perspective describes how Europe's ageing population is straining healthcare delivery, with dementia among the conditions accompanying longer lives, and proposes a 24-36 month EU agenda including workforce and care coordination measures. It is a policy commentary and does not report any treatment, cure or prevention of Alzheimer's disease.
-
Dementia is a known risk factor for delirium.
Why it matters
This narrative review reports that delirium superimposed on dementia is associated with poorer clinical outcomes than either condition alone, including accelerated cognitive and functional decline. Prevention remains the most effective management strategy, and multicomponent non-pharmacological interventions carried out by a multidisciplinary team have demonstrated benefits in reducing delirium incidence.
-
Dementia risk is influenced by biological and lifestyle factors as well as broader socioeconomic conditions; however, the extent to which socioeconomic deprivation creates structural exposures that affect cognitive aging remains unclear.
Why it matters
Neighborhood deprivation was linked to dementia diagnosis in partially adjusted models, but this link was no longer significant after accounting for individual factors like education. This suggests neighborhood deprivation may not independently predict dementia risk.
-
The behavioural and mental health needs of people with PWS result from the interactions between biological vulnerabilities associated with having PWS and living in a changing and demanding environment.
Why it matters
This paper describes the mental health and behavioral needs of people with Prader-Willi syndrome, a rare genetic neurodevelopmental condition. It reports no findings on treating, curing, or preventing Alzheimer's disease.
-
Six key themes were identified: Inadequate preparation, guidance and access to appropriate resources; Taboo and misunderstanding: talking about death; Dementia as a terminal illness and the role of palliative care; Key time points, critical events and decisions; Planning ahead not in reality; Family issues and dynamics.
Why it matters
This qualitative inquiry identified themes including inadequate preparation and resources, taboo around talking about death, and that planning ahead was 'not in reality' for families. It found that limited resources, poor access, and workforce shortages undermined efforts to enable living and dying at home, and calls for dementia-appropriate policies and adapted advance care planning.
-
Geographical differences in Alzheimer’s disease and related dementias (ADRD) prevalence may be driven by under-diagnosis due to insufficient healthcare access.
Why it matters
In 591 Central Appalachian counties, Appalachian counties had lower dementia prevalence than non-Appalachian counties in rural compared to urban areas, and this difference weakened after adjusting for broadband access. Broadband presence and higher household broadband proportion were associated with lower dementia prevalence after adjusting for poverty.
-
Patient access to innovative care for complex conditions like schizophrenia remains limited by systemic, clinical and policy-level barriers.
Why it matters
This study examined barriers to care for cognitive impairment in schizophrenia across European countries and found that structural issues like fragmented care and limited reimbursement are the main obstacles. It does not address Alzheimer's disease treatment, cure, or prevention.
-
30/100
Our study underscores the role of telehealth in increasing AWV uptake and facilitating cognitive assessments.
Why it matters
In Traditional Medicare, telehealth users had a 10.2 percentage point higher rate of Annual Wellness Visit uptake than non-users, and 7% of those visits were delivered by telehealth. This is a preliminary analysis of 2020 data only, and the researchers have not yet extended it to Medicare Advantage beneficiaries.
-
Of 6,911,104 patients (min=Idaho: 45,160; max=California: 2.46 million), we observed a substantial difference in overall diagnosed prevalence across states of residence: Oregon and Montana had the highest diagnosed prevalence (6.6% and 6.5%, respectively); New Mexico had the lowest (2.3%).
Why it matters
Across eight Western U.S. states, diagnosed prevalence of Alzheimer's disease and related dementias was lower in rural and low-commuting areas than in urban and high-commuting areas. Diagnosed prevalence also varied substantially by state, from 6.6% in Oregon to 2.3% in New Mexico.
-
30/100
These findings highlight a persistent spatial mismatch between population needs and care infrastructure.
Why it matters
This mapping study found that areas with the most older adults needing dementia care often have the fewest care facilities, especially in the rural South, Great Plains, and Mountain West. Specialized services like adult day programs and Alzheimer's centers were mostly located in cities.
-
We found that a higher baseline sum of stress events was associated with greater risk of conversion from baseline stable cognition to mild cognitive impairment (MCI) or dementia at follow up, even when controlling for age, sex, premorbid level of intellectual disability, site, clinical latency between assessments, and the presence of anxiety or depression (odds ratio = 1.53, p = 0.021).
Why it matters
In adults with Down syndrome, a higher number of life stressors at baseline was linked to a greater risk of progressing to mild cognitive impairment or dementia at follow-up. The findings suggest that life stress may predict cognitive decline in this group, though the study does not prove that stress causes dementia.
-
During the one-year follow-up, the intervention group showed a significant increase in mean cognitive scores (Addenbrooke's cognitive examination), rising from 73.94 to 82.32 (p < 0.001).
Why it matters
In these interim results, the multidomain intervention group's mean cognitive scores rose significantly over one year, and the control group also improved modestly, with a significant difference between groups at the end of follow-up. The authors call these interim results promising and say the intervention could be integrated into primary health care if found effective, but this is not yet a confirmed treatment or cure.
-
30/100
As dementia progresses to advanced stages, the need for compassionate and person-centred care becomes paramount.
Why it matters
This presentation describes the experience of a Flemish healthcare company providing at-home palliative care for people with dementia, covering trust with families, complex needs, and use of technology and community resources. It offers practical insights from case studies and qualitative data on supporting comfort and continuity at home, not a treatment or cure.
-
The FFMQ-15 may reflect different experiences of mindfulness among Black caregivers of PWD.
Why it matters
This study found that some items on a mindfulness questionnaire may perform differently in Black compared to White dementia caregivers. It addresses caregiver assessment, not treating, curing, or preventing Alzheimer's disease.
-
Dementia, the most common subtype of which is Alzheimer’s disease, represents a significant global and social health challenge.
Why it matters
This review discusses combining AI with biomarkers from imaging, speech, movement, and cognitive data to improve risk assessment, diagnosis, and monitoring of Alzheimer's disease. It describes potential future tools and does not report a treatment, cure, or prevention.
-
W treat showed a strong direct association with W cost (0.99).
Why it matters
This study found that willingness to pay was strongly associated with willingness to treat, and that reducing payment barriers has a greater impact on real-world adoption of lecanemab than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay, informing patient-centred clinical decision pathways.
-
• A novel semi-immersive VR driving simulator (VRDS) for institutionalized older adults with advanced dementia. • The VRDS integrates realistic driving with a virtual environment to stimulate implicit memory and improve cognitive function. • Statistical analyses indicate improvements in game and mood scores over repeated sessions. • The system’s performance logging provides objective measures of implicit learning and motor adaptation in advanced dementia. • The logging system offers a practical alternative to standard cognitive assessments in advanced dementia.
Why it matters
This small pilot study found that a virtual reality driving simulator was linked to improved game and mood scores over repeated sessions in people with advanced dementia. It is preliminary and does not show that this approach prevents or cures dementia.
-
30/100
Frequently occurring copathology, most commonly with Alzheimer disease, leads to greater cognitive decline, increased likelihood of admission to a long-term care facility, and a higher risk of mortality.
Why it matters
This article reviews the diagnosis, prodromal phase and management of dementia with Lewy bodies, including biomarkers such as phosphorylated α-synuclein in cutaneous nerve fibres and the CSF α-synuclein seed amplification assay. It focuses on earlier diagnosis and management of dementia with Lewy bodies and does not report a treatment, cure or prevention for Alzheimer's disease.
-
As rates of dementia increase, the need for care is clear.
Why it matters
This paper discusses how current theories of dementia care need to account for decline, dependency and loss when applied to end-of-life care. It does not test any treatment, cure or prevention.
-
How should I approach advance care planning (ACP) and goals of care (GOC) discussions with patients living with dementia?
Why it matters
This paper addresses how clinicians should approach advance care planning and goals of care discussions with patients living with dementia. It is about communication and care planning, not treating, curing or preventing Alzheimer's disease.
-
Number of patients on the unit with an ACP increased between May 2024 and January 2025, from a low of 0% on 03/06/24 to a high of 53% on 12/12/24.
Why it matters
This quality improvement project on a specialist dementia unit increased the proportion of patients with an advance care plan by introducing a weekly ACP slot. It is about end-of-life planning in care, not treating, curing or preventing Alzheimer's disease.
-
MA-PD enrollees had significantly lower utilization of PIMs than standalone PDP enrollees: a 0.7 percentage-point [95% CI: 0.5, 0.8] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia; a 3.1 percentage-point [2.6, 3.5] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia and a history of falls; and a 0.5 percentage-point [0.4, 0.6] lower prevalence of high-risk medications in older adults.
Why it matters
This study found that people with dementia in Medicare Advantage prescription drug plans were prescribed potentially inappropriate medications less often than those in standalone Medicare drug plans. It does not test any treatment for Alzheimer's disease itself, but it suggests that features of certain Medicare plans may support safer prescribing for people with dementia.
-
30/100
As the population of older adults continues to grow, the prevalence of dementia is increasing dramatically.
Why it matters
This reflection notes that caring for an older adult with dementia is linked to high chronic stress that may harm caregiver health. It offers no tested treatment or cure, but suggests that grief and guilt should be assessed when supporting caregivers.
-
Though biomarker assessments showed significant Aβ reduction for both anti-amyloid therapies, no direct correlation with clinical outcomes was observed, limiting their use as surrogate endpoints.
Why it matters
This clinical evaluation of medicines for mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan found that although anti-amyloid therapies significantly reduced amyloid-beta, this reduction did not directly correlate with clinical outcomes. Safety evaluation focused on amyloid-related imaging abnormalities, a key risk of anti-amyloid antibody treatments.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Antimicrobial therapy in palliative care: an overview
- Association of Multimorbidity, Disease Clusters, and Modification by Genetic Factors With Risk of Dementia
- Mediterranean diet, gut microbiota, and cognitive decline in older adults with obesity/overweight and metabolic syndrome: a prospective cohort study
- Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts
- Delirium as a Precursor to Dementia in Elderly Type 2 Diabetes Mellitus Patients
- Review of brief cognitive tests for patients with suspected dementia
- Pulmonary function, muscle strength and mortality in old age
- Assessment of Mental Status
- Clinical Characteristics, Frailty, and Mortality of Residents With COVID-19 in Nursing Homes of a Region of Madrid
- Contribution of Modifiable Midlife and Late-Life Vascular Risk Factors to Incident Dementia